Clinical management of prolactinomas.
Prolactinomas are benign, sporadic pituitary tumours that typically present with amenorrhoea and galactorrhoea in women, and hypogonadism and space-occupying effects in men. Hyperprolactinaemic hypogonadism in either sex is associated with reduced bone mineral density, which may be progressive and only partially reversible. For most microprolactinomas, dopamine agonists are the treatment of choice, achieving normoprolactinaemia and restoring gonadal function in 80-90% of cases. Trans-sphenoidal surgery is curative in 60%, but may be complicated by hypopituitarism and is usually reserved for patients with dopamine agonist intolerance or resistance. A subgroup of patients with small tumours, mild symptoms and normal gonadal function may be monitored without specific treatment--the risk of tumour expansion is small. Macroprolactinomas should be treated medically, dopamine agonists controlling prolactin secretion and achieving significant tumour shrinkage in 80% of cases, whereas surgery is curative in only a quarter. Cabergoline is the dopamine agonist of choice in most situations, being better tolerated and more effective than bromocriptine. Quinagolide is an effective alternative. Dopamine agonist withdrawal or dose reduction should be considered after 2-5 years therapy. Oestrogens may be used with caution in women with prolactinomas.
Webster
J
J
Department of Endocrinology and Diabetes, Northern General Hospital, Sheffield, UK.
D015519:Bone Density; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000627:therapeutic use; D004351:Drug Resistance; D004873:Ergolines / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007006:Hypogonadism / Q000209:etiology; D008297:Male; D010911:Pituitary Neoplasms / Q000503:physiopathology / Q000601:surgery / Q000628:therapy*; D011247:Pregnancy; D015175:Prolactinoma / Q000628:therapy*
D018491:Dopamine Agonists; D004873:Ergolines; D000077465:Cabergoline